Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call
1-800-KARMANOS (1-800-527-6266)
or request an appointment below
Back to Results
A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.
Cancer Categories
Lung
Karmanos Trial ID
2014-002
NCT ID
NCT02178163
Age Group
Adult
Scope
Local
Phase
Phase II
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
Phase II
Principal Investigator
Gerold
Bepler, M.D., Ph.D.
View Profile
Objective:
Primary:
To assess the percentage of advanced non-small cell lung cancer patients in whom therapy can be initiated based on genomic analysis of tumor specimens.
Secondary:
To estimate the percentage of patients in whom genomic analysis can be performed.
To assess the progression free survival and response rate in patients who start therapy based on the genomic analyses results.
Request an Appointment
Refer a Patient
NCI Dictionary of Cancer Terms
KCI Clinical Trials App
Eligibility
Locations
Applicable Disease Site
Therapies | Drugs | Devices
Eligibility
Eligibility
Inclusion Criteria:
Stage IV or recurrent Non-Small Cell Lung Cancer patients who either have archival tissue for genomic analysis or are willing to undergo a new biopsy to obtain tumor tissue for genomic analysis. Patients whose tumor has already undergone genomic analysis will be eligible.
Zubrod performance status 0-2
Life expectancy >= 3 months
Absolute neutrophil count of > 1.5 x 10^9/L
Platelet count > 100,000 x 10^9/L
Serum creatinine =< 1.5 times the institutional upper limit of normal (ULN) or calculated creatinine clearance (Cockcroft-Gault formula) of > 45 mL/min
Serum bilirubin =< 1.5 X ULN
Transaminases (serum glutamic oxaloacetic transaminase [SGOT] and/or serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times institutional ULN and alkaline phosphatase =< 2.5 times ULN, unless patient has liver metastases and the managing physician believes that the elevation in liver enzymes is only related to the liver metastases
Laboratory tests should be done within 30 days of enrollment on the trial
A biopsy of the patient's tumor for genomic profiling is required; this biopsy specimen can be an already obtained diagnostic specimen provided the patient has not received systemic therapy since the biopsy has been obtained and was obtained within 60 days of trial enrollment. The biopsy material cannot be from a tumor site that has been radiated.
Signed informed consent that details the investigational nature of the study according to institutional and federal guidelines
Exclusion Criteria:
Patients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patient
Serious medical illness including but not limited to uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6 months of registration, history of chronic active hepatitis or history of human immunodeficiency virus (HIV) or an active bacterial infection will not be eligible
Pregnant or lactating women; female patients of child bearing potential will be informed that if they do enroll on a therapeutic trial, based on the genomic analyses, that they may not be able to enroll on a clinical trial if they are pregnant; all sexually active patients will be informed that patients enrolling on a therapeutic trial have to use contraceptive methods to prevent pregnancy
Locations
Locations
Karmanos Cancer Institute - Detroit Headquarters
4100 John R
Detroit, MI 48201
Get Directions
Phone:
800-527-6266
Karmanos Cancer Institute at McLaren Bay Region
3140 W Campus Dr.
Bay City, MI 48706
Get Directions
Phone:
989-667-2370
Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center
1221 South Drive
Mount Pleasant, MI 48858
Get Directions
Phone:
989-772-6811
Karmanos Cancer Institute at McLaren Clarkston
5680 Bow Pointe Dr
Clarkston, MI 48346
Get Directions
Phone:
248-922-6650
Karmanos Cancer Institute at McLaren Flint
4100 Beecher Rd
Flint, MI 48532
Get Directions
Phone:
810-342-3800
Karmanos Cancer Institute at McLaren Greater Lansing - Medical Oncology and Hematology
3520 Forest Rd.
Lansing, MI 48910
Get Directions
Phone:
517-975-9500
Karmanos Cancer Institute at McLaren Lapeer Region
1295 Barry Drive
Lapeer, MI 48446
Get Directions
Phone:
800-527-6266
Karmanos Cancer Institute at McLaren Macomb
1080 Harrington Blvd
Mount Clemens, MI 48043
Get Directions
Phone:
586-493-7510
Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey
560 W Mitchell St
Petoskey, MI 49770
Get Directions
Phone:
231-487-3390
Karmanos Cancer Institute at McLaren Port Huron
1221 Pine Grove Ave
Port Huron, MI 48060
Get Directions
Phone:
810-982-5200
Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills
31995 Northwestern Hwy
Farmington Hills, MI 48334
Get Directions
Phone:
800-527-6266
Applicable Disease Site
Applicable Disease Site
Lung
Therapies, Drugs, Devices
Therapies | Drugs | Devices
Therapies
Biological Therapy, Chemotherapy, Immunotherapy
Loading...